Kolon Life Science (102940) is accelerating its global commercialization strategy by expanding indications for its next-generation gene therapy candidate. The company plans to publish preclinical data in academic journals for scientific validation before pursuing co-development and licensing-out discussions.
Kolon Life Science announced on the 23rd that it is expanding indications for its anticancer gene therapy candidate 'KLS-3021' to include head and neck squamous cell carcinoma and triple-negative breast cancer, with related research currently underway. The company plans to disclose preclinical data from additional indications through papers and academic conference presentations, using these findings in discussions with global partners.
KLS-3021 is an anticancer gene therapy featuring therapeutic genes (PH-20, IL-12, sPD1-Fc) loaded onto a recombinant vaccinia virus with enhanced cancer cell selectivity. The treatment is designed to combine the virus's direct tumor-killing mechanism with tumor stroma degradation, promoting immune cell infiltration and inducing anticancer immune responses.
Head and neck squamous cell carcinoma and triple-negative breast cancer, the newly expanded indications, are high-risk cancer types with poor prognosis and limited treatment options in advanced and recurrent stages. Response rates to existing immunotherapy drugs remain low, making these areas in need of new treatment strategies. Kolon Life Science aims to publish its head and neck cancer paper in the first half of the year and plans to submit triple-negative breast cancer research results within this year.
The company previously published preclinical results for prostate cancer and cutaneous squamous cell carcinoma in papers and posters. In those studies, KLS-3021 significantly reduced tumor size with a single administration. In metastatic tumor models, it demonstrated therapeutic effects not only in primary tumors but also in adjacent lymph node metastases.
Another pipeline candidate, 'KLS-2031,' is a recombinant adeno-associated virus-based gene therapy designed to express GAD65, GDNF, and IL-10 genes. Research focuses on diabetic peripheral neuropathy based on mechanisms of neuroinflammation suppression and pain signal regulation, with additional indication expansion under review.
Kolon Life Science's strategy is to enhance pipeline value through indication expansion and data accumulation, using this foundation to expand global co-development and technology transfer discussions. "We continue to validate and publish the expansion potential of our candidates to secure objective evidence," said Kim Sun-jin, CEO of Kolon Life Science. "We will strengthen global partnerships based on our accumulated data."